Inventor · disambiguated record
Haruo Sugiyama
Also filed as: SUGIYAMA HARUO
75 granted patents·37 pending applications·786 citations·filing 1986–2024
99Inventor score
Files withINT INST CANCER IMMUNOLOGY INC48SUGIYAMA HARUO28NITTO DENKO CORP11UNIV OSAKA9CHUGAI PHARMACEUTICAL CO LTD2
Top patents by PatentIndex Score
112 records- 0197US8778350B2Method of treating cancer with an HLA-A*3303-restricted WT1 peptide and pharmaceutical composition comprising the sameSUGIYAMA HARUO·Filed 2012·Granted Jul 15, 2014·16 cites·12 claims
- 0296US10988540B2AntibodyUNIV OSAKA·Filed 2020·Granted Apr 27, 2021·4 cites·12 claims
- 0396US7622119B2Cancer antigen peptides derived from WT1INT INST CANCER IMMUNOLOGY INC·Filed 2005·Granted Nov 24, 2009·33 cites·10 claims
- 0496US7608685B1Tumor antigen based on products of the tumor suppressor gene WT1INT INST CANCER IMMUNOLOGY INC·Filed 2005·Granted Oct 27, 2009·38 cites·9 claims
- 0596US7517950B2Tumor antigen based on products of the tumor suppressor gene WT1INT INST CANCER IMMUNOLOGY INC·Filed 2006·Granted Apr 14, 2009·35 cites·9 claims
- 0696US6277832B1Growth inhibitor for leukemia cells comprising antisense oligonucleotide derivative to wilms tumor gene (wt1)KISHIMOTO TADAMITSU·Filed 2000·Granted Aug 21, 2001·89 cites·4 claims
- 0795US7666985B2HLA-A24-restricted cancer antigen peptidesINT INST CANCER IMMUNOLOGY INC·Filed 2008·Granted Feb 23, 2010·31 cites·4 claims
- 0895US7390871B2Tumor antigen based on products of the tumor suppressor gene WT1INT INST CANCER IMMUNOLOGY INC·Filed 2005·Granted Jun 24, 2008·24 cites·9 claims
- 0994US8105604B2WT1 modified peptideSUGIYAMA HARUO·Filed 2009·Granted Jan 31, 2012·20 cites·5 claims
- 1093US8557779B2Cancer vaccine compositionSUGIYAMA HARUO·Filed 2008·Granted Oct 15, 2013·14 cites·4 claims
- 1193US7807792B2Tumor antigen based on products of the tumor suppressor gene WT1INT INST CANCER IMMUNOLOGY INC·Filed 2009·Granted Oct 5, 2010·15 cites·12 claims
- 1292US8968745B2Method of treating cancer with an HLA-A*3303-restricted WT1 peptide and pharmaceutical composition comprising the sameINT INST CANCER IMMUNOLOGY INC·Filed 2013·Granted Mar 3, 2015·5 cites·12 claims
- 1392US8945578B2Method of treating cancer with an HLA-A*3303-restricted WT1 peptide and pharmaceutical composition comprising the sameINT INST CANCER IMMUNOLOGY INC·Filed 2013·Granted Feb 3, 2015·5 cites·12 claims
- 1492US8933038B2Method of treating cancer with an HLA-A*3303-restricted WT1 peptide and pharmaceutical composition comprising the sameINT INST CANCER IMMUNOLOGY INC·Filed 2013·Granted Jan 13, 2015·5 cites·12 claims
- 1592US8388975B2Cancer antigen peptides derived from WT1SUGIYAMA HARUO·Filed 2009·Granted Mar 5, 2013·15 cites·6 claims
- 1692US7420034B2HLA-A24-restricted cancer antigen peptidesDAINIPPON SUMITOMO PHARMA CO·Filed 2003·Granted Sep 2, 2008·40 cites·4 claims
- 1791US11707512B2Cancer vaccine compositionINT INST CANCER IMMUNOLOGY INC·Filed 2019·Granted Jul 25, 2023·2 cites·20 claims
- 1891US10654931B2AntibodyUNIV OSAKA·Filed 2016·Granted May 19, 2020·5 cites·8 claims
- 1991US10426822B2Cancer vaccine compositionINT INST CANCER IMMUNOLOGY INC·Filed 2016·Granted Oct 1, 2019·6 cites·17 claims
- 2091US9403886B2Tumor antigen based on products of the tumor suppressor gene WT1SUGIYAMA HARUO·Filed 2008·Granted Aug 2, 2016·11 cites·8 claims
- 2191US9266932B2Cancer antigen helper peptideSUGIYAMA HARUO·Filed 2010·Granted Feb 23, 2016·11 cites·12 claims
- 2291US8759483B2HLA-A* 3303-restricted WT1 peptide and pharmaceutical composition comprising the sameSUGIYAMA HARUO·Filed 2007·Granted Jun 24, 2014·5 cites·5 claims
- 2391US7342092B2Cancer antigen peptide formulationsINT INST CANCER IMMUNOLOGY INC·Filed 2003·Granted Mar 11, 2008·33 cites·7 claims
- 2490US10759840B2Cancer antigen helper peptideINT INST CANCER IMMUNOLOGY INC·Filed 2017·Granted Sep 1, 2020·2 cites·10 claims
- 2590US10093977B2Cancer antigen-specific T-cell receptor gene, peptide encoded by the gene, and use of themSUGIYAMA HARUO·Filed 2008·Granted Oct 9, 2018·6 cites·3 claims
- 2690US9272026B2HLA-A*1101-restricted WT1 peptide and pharmaceutical composition comprising the sameINT INST CANCER IMMUNOLOGY INC·Filed 2013·Granted Mar 1, 2016·9 cites·2 claims
- 2789US7030212B1Tumor antigen based on products of the tumor suppressor gene WT1HARUO SUGIYAMA·Filed 1999·Granted Apr 18, 2006·60 cites·9 claims
- 2888US10525096B2Immunotherapy for angiogenic diseaseINT INST CANCER IMMUNOLOGY INC·Filed 2015·Granted Jan 7, 2020·2 cites·6 claims
- 2987US9803246B2Receptor gene for peptide cancer antigen-specific T cellSUGIYAMA HARUO·Filed 2012·Granted Oct 31, 2017·5 cites·10 claims
- 3087US7378384B2WT1 substitution peptidesINT INST CANCER IMMUNOLOGY INC·Filed 2003·Granted May 27, 2008·22 cites·6 claims
- 3187US6225051B1Method of detecting solid cancer cells and tissue atypia and method of testing tissues for use in bone marrow transplantation and peripheral blood stem cell transplantationSUGIYAMA HARUO·Filed 1997·Granted May 1, 2001·80 cites·7 claims
- 3287US2024360222A1AntibodyUNIV OSAKA·Filed 2024·Application pending·0 cites
- 3386US10648036B2Receptor gene for peptide cancer antigen-specific T cellINT INST CANCER IMMUNOLOGY INC·Filed 2015·Granted May 12, 2020·3 cites·8 claims
- 3486US9119801B2Cancer vaccine compositionINT INST CANCER IMMUNOLOGY INC·Filed 2013·Granted Sep 1, 2015·5 cites·5 claims
- 3585US10669584B2Cancer antigen-specific T-cell receptor gene, peptide encoded by the gene, and use of themINT INST CANCER IMMUNOLOGY INC·Filed 2014·Granted Jun 2, 2020·2 cites·8 claims
- 3685US8288355B2siRNA specific to WT1 17AA(−)isoform and use thereofSUGIYAMA HARUO·Filed 2007·Granted Oct 16, 2012·9 cites·18 claims
- 3785US6034235AGrowth inhibitor for leukemia cell comprising antisense oligonucleotide derivative to wilms tumor gene (WT1)KISHIMOTO TADAMITSU·Filed 1996·Granted Mar 7, 2000·58 cites·8 claims
- 3884US10071051B2WT1 peptide cancer vaccine composition for transdermal administrationNITTO DENKO CORP·Filed 2014·Granted Sep 11, 2018·3 cites·11 claims
- 3983US10124046B2HLA-DR-binding antigen peptide derived from WT1INT INST CANCER IMMUNOLOGY INC·Filed 2013·Granted Nov 13, 2018·4 cites·26 claims
- 4082US8653038B2HLA-A* 1101-restricted WT1 peptide and pharmaceutical composition comprising the sameSUGIYAMA HARUO·Filed 2007·Granted Feb 18, 2014·3 cites·11 claims
- 4182US8142575B2High strength aluminum alloy fin material for heat exchanger and method for production thereofOKI YOSHITO·Filed 2005·Granted Mar 27, 2012·7 cites·27 claims
- 4281US8735357B2Method of inducing antigen-specific T cellsSUGIYAMA HARUO·Filed 2002·Granted May 27, 2014·9 cites·6 claims
- 4381US7824865B2Method for examining WT1-related diseaseSUGIYAMA HARUO·Filed 2005·Granted Nov 2, 2010·6 cites·4 claims
- 4480US10654892B2Method for activating helper T cellSUGIYAMA HARUO·Filed 2011·Granted May 19, 2020·3 cites·20 claims
- 4580US10139395B2Method for activation of helper T cell and composition for use in the methodSUGIYAMA HARUO·Filed 2008·Granted Nov 27, 2018·2 cites·19 claims
- 4679US2022313770A1Immunotherapy for angiogenic diseaseINT INST CANCER IMMUNOLOGY INC·Filed 2022·Application pending·0 cites
- 4778US11413322B2Immunotherapy for angiogenic diseaseINT INST CANCER IMMUNOLOGY INC·Filed 2019·Granted Aug 16, 2022·0 cites·5 claims
- 4877US11369656B2Immunotherapy for angiogenic diseaseINT INST CANCER IMMUNOLOGY INC·Filed 2019·Granted Jun 28, 2022·0 cites·6 claims
- 4977US9539299B2Combination therapy with WT1 peptide vaccine and temozolomideINT INST CANCER IMMUNOLOGY INC·Filed 2012·Granted Jan 10, 2017·2 cites·4 claims
- 5077US2023357390A1ANTI-CD98hc ANTIBODYUNIV OSAKA·Filed 2023·Application pending·0 cites
Showing the top 50 of 112 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →